Published on November 16, 2009 at 5:57 AM
Post hoc analysis of Phase 3 study data presented at national psychiatric meeting
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse-. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years. The post hoc analysis showed that patients demonstrated an improvement in emotional lability composite CPRS-RS scores while taking Vyvanse as compared to placebo. These results were presented recently at a psychiatric meeting in Honolulu.
"Children taking ADHD medications can experience emotional lability, often described as frequent changes in emotions or mood. Therefore, evaluating the impact of ADHD treatments, including Vyvanse, on children's emotional lability may be important for parents and health care professionals when assessing a child's treatment plan," said Ann C. Childress, MD, study investigator and president of the Center for Psychiatry and Behavioral Medicine, Inc. in Las Vegas.
Source: Porter Novelli
61ba286d-5b3b-4047-95a2-27f2235034f8|0|.0
Posted in: Child Health News | Drug Trial News
Tags: Abdominal Pain, Arteriosclerosis, Bipolar Disorder, Blood Pressure, Cardiovascular Disease, CDC, Depression, Drug Abuse, Glaucoma, Headache, Hypersensitivity, Hyperthyroidism, Insomnia, Nausea, Placebo, Psychiatry, Psychosis, Stroke, Vomiting